Metastatic Breast Cancer
Conference Coverage
Genomic instability varies between breast cancer subtypes
Personalized medicine could be a step closer with the discovery that TNBC and ER+ breast cancers should have different genomic instability...
Conference Coverage
Ongoing HER2 breast cancer therapy may cost an additional $68,000 per patient
A Canadian study suggests that significant increases in cost per patient can be expected if funding policies don’t evolve to meet treatment needs...
Conference Coverage
1 in 7 breast cancers are overdiagnosed
The model takes into account indolent tumors and estimates one in seven screen-detected cancers will be overdiagnosed with biennial screening.
Conference Coverage
Vitamin D counters bone density loss with aromatase inhibitors
Researchers found no difference in bone mineral decline among breast cancer patients treated with aromatase inhibitors and those treated with...
Conference Coverage
Metformin does not improve outcomes in early breast cancer
Conference Coverage
Genomic profiling can improve PFS in metastatic breast cancer
Genomic testing for cancer is effective, experts say. Targeted therapy may be needed when genomic alterations are present.
Conference Coverage
CDK4/6 inhibitors: Should they be stopped in the face of COVID-19?
Two small studies suggest a high probability of disease progression.
Conference Coverage
Novel SERD reduces risk of death by 30% in HR+ breast cancer
First oral SERD demonstrates statistically significant and clinically meaningful improvement in survival in patients with ER-positive/HER2-...
Conference Coverage
Black women most at risk for lymphedema after ALND
Axillary lymph node dissection is the main risk factor for lymphedema, but now a new study shows that 67% of patients needing the procedure are...
Conference Coverage
In metastatic breast cancer, primary resections on the decline
The trend follows randomized, controlled trials that showed no survival benefit to surgery.
Conference Coverage
What’s hot at the world’s premiere breast cancer meeting
An important study of an investigational oral agent for postmenopausal women who have been treated for ER positive advanced breast cancer...